List of Zavzpret drug patents
Zavzpret is owned by Pfizer.
Zavzpret contains Zavegepant Hydrochloride.
Zavzpret has a total of 3 drug patents out of which 0 drug patents have expired.
Zavzpret was authorised for market use on 09 March, 2023.
Zavzpret is available in spray, metered;nasal dosage forms.
Zavzpret can be used as administration of zavegepant for acute treatment of migraine with or without aura.
Drug patent challenges can be filed against Zavzpret from 2027-03-10.
The generics of Zavzpret are possible to be released after 07 October, 2031.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7220862 | PFIZER | Calcitonin gene related peptide receptor antagonists |
Jan, 2024
(7 months from now) | |
| US8481546 | PFIZER | CGRP receptor antagonist |
Oct, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7314883 | PFIZER | Anti-migraine treatments |
Dec, 2023
(6 months from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Mar 9, 2028 |
Drugs and Companies using ZAVEGEPANT HYDROCHLORIDE ingredient
NCE-1 date: 2027-03-10
Market Authorisation Date: 09 March, 2023
Treatment: Administration of zavegepant for acute treatment of migraine with or without aura
Dosage: SPRAY, METERED;NASAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic